• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

    2/9/24 9:49:30 AM ET
    $SWAV
    Medical/Dental Instruments
    Health Care
    Get the next $SWAV alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 SHOCKWAVE MEDICAL INC COMMON STOCK Cusip #82489T104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #82489T104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,014,788 Item 6: 0 Item 7: 2,039,230 Item 8: 0 Item 9: 2,039,230 Item 11: 5.521% Item 12: HC Cusip #82489T104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,039,230 Item 8: 0 Item 9: 2,039,230 Item 11: 5.521% Item 12: IN Item 1(a). Name of Issuer: SHOCKWAVE MEDICAL INC Item 1(b). Address of Issuer's Principal Executive Offices: 5403 Betsy Ross Drive Santa Clara, CA 95054 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 82489T104 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 2,039,230 (b) Percent of Class: 5.521% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 2,039,230 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of SHOCKWAVE MEDICAL INC. No one other person's interest in the COMMON STOCK of SHOCKWAVE MEDICAL INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Diversifying Solutions LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of SHOCKWAVE MEDICAL INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $SWAV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWAV

    DatePrice TargetRatingAnalyst
    4/5/2024Outperform → Peer Perform
    Wolfe Research
    3/27/2024$368.00Buy
    CL King
    9/29/2023$218.00Neutral
    UBS
    7/10/2023$291.00 → $335.00Equal-Weight → Overweight
    Morgan Stanley
    5/30/2023$291.00Equal-Weight
    Morgan Stanley
    3/15/2023$240.00Buy
    Needham
    12/16/2022$285.00Buy
    Deutsche Bank
    12/12/2022$300.00 → $235.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Sarepta Therapeutics Set to Join S&P MidCap 400

      NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For

      5/29/24 5:48:00 PM ET
      $JNJ
      $SPGI
      $SRPT
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance

    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

      SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

      2/13/24 5:13:59 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

      SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

      2/9/24 9:49:30 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by ShockWave Medical Inc.

      SC 13G - Shockwave Medical, Inc. (0001642545) (Subject)

      2/8/24 10:17:35 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Financials

    Live finance-specific insights

    See more
    • Shockwave Medical Reports First Quarter 2024 Financial Results

      SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to

      5/6/24 4:05:00 PM ET
      $JNJ
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Johnson & Johnson to Acquire Shockwave Medical

      Enhances Johnson & Johnson's Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech's Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ) and Shockwave Medical, Inc. (NASDAQ:SWAV) ("Shockwave") today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335

      4/5/24 6:31:00 AM ET
      $JNJ
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results

      SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent Highlights Recognized revenue of $203.0 million for the fourth quarter of 2023 and $730.2 million for the full year 2023, representing increases of 41% and 49%, respectively, from the same periods in 2022Initiated the full U.S. commercial launch of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheterGranted new physician and hospital reimbursement for

      2/15/24 4:03:00 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Francis Laura returned 4,784 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:42:11 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • Moll Frederic H returned 287,521 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:41:41 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • Papiernik Antoine returned 34,913 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:40:07 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ShockWave Medical downgraded by Wolfe Research

      Wolfe Research downgraded ShockWave Medical from Outperform to Peer Perform

      4/5/24 7:33:47 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • CL King initiated coverage on ShockWave Medical with a new price target

      CL King initiated coverage of ShockWave Medical with a rating of Buy and set a new price target of $368.00

      3/27/24 8:20:17 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on ShockWave Medical with a new price target

      UBS initiated coverage of ShockWave Medical with a rating of Neutral and set a new price target of $218.00

      9/29/23 7:46:27 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Shockwave Medical Inc.

      15-12G - Shockwave Medical, Inc. (0001642545) (Filer)

      6/10/24 4:33:25 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Shockwave Medical Inc.

      S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)

      5/31/24 4:38:18 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Shockwave Medical Inc.

      S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)

      5/31/24 4:28:57 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Leadership Updates

    Live Leadership Updates

    See more
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Sarepta Therapeutics Set to Join S&P MidCap 400

      NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For

      5/29/24 5:48:00 PM ET
      $JNJ
      $SPGI
      $SRPT
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance